To address this clinical issue, we evaluated the prognostic value of BLNLR and ΔNLR% before third cycle of treatment and combined the two to stratify the prognosis of patients with metastatic malignant melanoma treated with PD-1 inhibitors. The gene discussed is PDCD1; the disease is metastatic melanoma.